La vendita allo scoperto per Inozyme Pharma dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Inozyme Pharma. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Inozyme Pharma (NASDAQ:INZY) Azioni, Report sulle vendite allo scoperto

INOZYME PHARMA INC

Inozyme Pharma

Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.

Inozyme Pharma Inc

Based on LAURA Phase III trial results which showed patients who took&nbsp;TAGRISSO after CRT had a median progression-free survival of more than 3 years
MISSISSAUGA, ON, May 21, 2025 /CNW/ - Health Canada has granted a Notice of Compliance with conditions (NOC/c) for Tagrisso&#xAE; (osimertinib) for the treatment of patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations (either alone or in combination with other EGFR mutations) and whose disease has not progressed during or following platinum based chemoradiation therapy. A validated test is required to identify EGFR mutation-positive status prior to treatment.1
The conditional approval was based on results from the LAURA Phase III trial, which were presented during the Plenary Session at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4432011-1&amp;h=2967221920&amp;u=https%3A%2F%2Fwww.nejm.org%2F&amp;a=The+New+England+Journal+of+Medicine">The New England Journal of Medicine</a>.2
Tagrisso&nbsp;reduced the risk of disease progression or death by 84% compared to placebo (hazard ratio 0.16; 95% confidence interval 0.10-0.24; p&lt;0.001) as assessed by blinded independent central review. Median progression-free survival (PFS) was 39.1 months in patients treated with&nbsp;Tagrisso&nbsp;versus 5.6 months for placebo.2&nbsp;Overall survival (OS) results remain immature at this current analysis. The trial continues to assess OS as a secondary endpoint.2
Each year in Canada, 32,000 people are diagnosed with lung cancer3, and 80-85% of these patients are diagnosed with NSCLC, the most common form of lung cancer.4 Approximately 15% of NSCLC patients in Canada have&nbsp;EGFR mutations.5 Nearly one in five people diagnosed with NSCLC has an unresectable&nbsp;tumour.6

Biotech

News

Global

General

AstraZeneca Canada Announces Tagrisso Approved In Canada For Patients With Unresectable, Stage III EGFR-Mutated Non-Small Cell Lung Cancer

Waters Acquires Halo Labs, Terms Not Disclosed

DOGE might be slashing roles across federal agencies, but the department itself is on a hiring spree. According to a candidate who recently applied for a position, the hiring process involves a five-stage interview process that takes place over a couple of weeks.
What Happened: The applicant <a href="https://www.wired.com/story/doge-application-interview-process/">told</a> WIRED that the process began with a short screening call, followed by a technical assignment with an immediate deadline. Successful applicants then moved on to two in-depth technical interviews and finally a placement discussion to gauge fit and project alignment. 
According to the applicant, interviewed by the publication, salaries ranged from $120,000 to $190,000, which is in line with top federal pay grades. According to a former USDS insider, this range is not new, but some DOGE recruits with no experience in the public sector are allegedly <a href="https://www.benzinga.com/25/03/44186261/doge-staffers-reportedly-draw-hefty-salaries-funded-by-taxpayers-while-musk-pushes-for-wasteful-spending-cuts">earning as much or more than long-time civil servants</a>.
See Also: <a href="https://www.benzinga.com/news/25/05/45536753/trump-eyes-retirement-overhaul-that-could-push-billions-from-401ks-into-high-stakes-private-equity-funds-report">Trump Eyes Retirement Overhaul That Could Push Billions From 401(k)s Into High-Stakes Private Equity Funds: Report</a>
What to Know: The interviewee was asked to build a basic site to help analyze government regulations. This exercise seems to align closely with DOGE's reported push towards AI-driven deregulation. During the first 15-minute call, a recruiter mentioned some projects DOGE was likely to implement, including, according to the applicant, "leveraging AI to improve medical services for veterans," "streamlining federal aid applications from Americans who experience natural disasters like floods, hurricanes, and tornadoes," and "improving the Free Application for Federal Student Aid (FAFSA) and expanding Americans' access to financial assistance for higher education."
This new insight on DOGE's hiring process comes as controversies surrounding DOGE employees remain unresolved. Two people connected with DOGE were reportedly provided <a href="https://www.benzinga.com/news/25/04/45093187/ex-spacex-intern-and-doge-staffer-gain-access-to-nuclear-security-department-despite-lacking-top-clearance-r">accounts on classified U.S. government networks</a> that manage sensitive nuclear weapons data. A&nbsp;<a href="https://www.benzinga.com/25/04/44859945/whistleblower-alleges-doge-involved-in-major-cybersecurity-breach-at-us-labor-agency" target="_blank" rel="noreferrer noopener">whistleblower report</a>&nbsp;also alleged unauthorized data access at the National Labor Relations Board by DOGE officials.
On Tuesday, <a href="https://www.benzinga.com/media/25/05/45534314/elon-musk-just-got-grilled-on-doge-spending-hits-back-with-were-not-kings-here">Elon Musk, the face of DOGE, responded to questions</a> about its efficacy, saying, "We are advisers. We are not—we&#8217;re not kings here."
Read Next: <a href="https://www.benzinga.com/news/global/25/05/45537805/musks-starlink-could-sidestep-south-african-equity-rules-under-deal-aimed-at-calming-relations-ahead-of-trump-meeting-report">Musk&#8217;s Starlink Could Sidestep South African Equity Rules Under Deal Aimed At Calming Relations Ahead Of Trump Meeting: Report</a>
Photo: Shutterstock

Economics

DOGE Is Hiring Even As It Slashes Federal Jobs—Candidate Reveals A Fast-Paced Five-Step Interview Process With Six-Figure Salaries On The Table

Jefferies analyst David Chiaverini initiates coverage on KeyCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEY#NYSE">KEY</a>) with a Hold rating and announces Price Target of $18.

Price Target

Initiation

Analyst Ratings

Jefferies Initiates Coverage On KeyCorp with Hold Rating, Announces Price Target of $18

<a href="https://pr.report/amzv">Jaguar Health, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) ("Jaguar" or "the Company"), today announced that it has entered into definitive agreements for the purchase and sale of 246,306 shares of common stock at a purchase price of $6.09 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company agreed to issue to investors unregistered warrants to purchase up to 492,612 shares of common stock at an exercise price of $5.84 per share that will be immediately exercisable upon issuance and will expire on the earlier of (i) 24 months from the date of issuance, (ii) the consummation of a fundamental transaction and (iii) the consummation of a liquidation event. The closing of the offering is expected to occur on or about May 22, 2025, subject to the satisfaction of customary closing conditions.
H.C. Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.
The gross proceeds to the Company from the offering are expected to be approximately $1.5 million before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for general corporate purposes, including growth capital, working capital, operating expenses, repayment of outstanding convertible promissory notes that are not converted into Common Stock by holders, and capital expenditures.

Offerings

JAGX

Jaguar Health Prices $1.5M Registered Direct Offering Of 246,306 Shares At A Price Of $6.09/Share

Jefferies analyst David Chiaverini initiates coverage on First Horizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHN#NYSE">FHN</a>) with a Buy rating and announces Price Target of $25.

Jefferies Initiates Coverage On First Horizon with Buy Rating, Announces Price Target of $25

While there's simply no denying the remarkable ascent of e-commerce and technology juggernaut Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), even the biggest stalwarts of industry are not completely immune to broader fundamental pressure. As the U.S.<a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45337839/if-you-have-to-google-are-we-in-a-recession-you-probably-feel-like-it"> economy struggles under the weight of elevated inflation</a> and trade tariffs, AMZN stock finds itself caught in a sentiment tug-of-war.
On one hand, analysts can easily argue that the e-commerce behemoth represents the best house in the worst block. While consumers overall may be struggling to make ends meet, Amazon still commands the enviable moat of being the<a href="https://www.benzinga.com/insights/news/25/05/45496882/analyzing-amazon-com-in-comparison-to-competitors-in-broadline-retail-industry"> leading online retailer and marketplace</a> for third-party sellers. True, the company is making inroads into other ventures. However, approximately 75% of Amazon's revenue is tied to its core retail business.
At the same time, the company's Amazon Web Services (AWS) is a profit engine. Furthermore, cloud adoption is rising across various industries. With AWS representing one of the top global cloud brands, Amazon is in an excellent position to grab additional market share. As such, its<a href="https://www.benzinga.com/quote/AMZN"> growth curve</a> can accelerate alongside its profitability metrics.
On the other hand, the trajectory of AMZN stock has been far less impressive in recent sessions as compared to prior years. Since the beginning of January, AMZN is down about 7%. In the past 52 weeks, the equity has only gained about 11%, a rather pedestrian figure that has been eclipsed by the S&amp;P 500.
Financially, a major concern about the mainline e-commerce business is the razor-thin margins. While retail drives the top line, the profit margins are under pressure – a situation that's exacerbated by inflation and tariff threats. Smart money investors also appear to be betting skeptically about AMZN stock, with<a href="https://www.benzinga.com/insights/options/25/05/45519222/a-closer-look-at-amazon-coms-options-market-dynamics"> sentiment recently turning bearish</a> in the options market.
The Direxion ETFs: With AMZN capable of moving sharply in either direction, speculators seeking the possibility of quick profits may consider Direxion's Amazon-focused exchange-traded funds. Specifically, aggressive optimists may consider the Direxion Daily AMZN Bull 2X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZU#NASDAQ">AMZU</a>), which seeks 200% of the performance of the namesake equity. On the other end, the bears may consider the Direxion Daily AMZN Bear 1X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZD#NASDAQ">AMZD</a>), which is an inverse fund of AMZN.
Primarily, the utility of the AMZU and AMZD ETFs centers on convenience. Typically, speculators interested in either leveraged wagers or short positions must engage the options market. While derivatives offer incredible flexibility, they can also be complex instruments. With Direxion ETFs, these units can be bought and sold much like any other public security, thus mitigating the learning curve.
Still, prospective investors must be aware of the unique risks of Direxion's leveraged and inverse ETFs. First, these products can be unusually volatile, so caution is warranted. Second, these funds are designed for exposure lasting no longer than one day. Beyond this recommended holding period, investors may incur value decay due to the daily compounding effect.
The AMZU ETF: After starting off the year auspiciously, the Direxion Daily AMZN Bull 2X Shares stumbled under the economic pressure, falling about 23%.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
<ul class="wp-block-list">
<li>With the Trump administration making progress regarding trade policies, AMZU has enjoyed robust near-term momentum, gaining almost 46% in the trailing month.</li>
<li>Currently, AMZU is trading above its 50-day moving average (DMA) but below its 200 DMA. Moving forward, its next natural target is the $35 level.</li>
</ul>
<figure class="wp-block-image"><img loading="lazy" decoding="async" width="1030" height="628" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21080949/image-263.png" alt="" class="wp-image-922680" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21080949/image-263.png 1030w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21080949/image-263-300x183.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21080949/image-263-1024x624.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21080949/image-263-768x468.png 768w" sizes="(max-width: 1030px) 100vw, 1030px" /></figure>
The AMZD ETF: Tripping out of the gate, the Direxion Daily AMZN Bear 1X Shares started looking lively later in the year as tariffs spared broader bearishness.
<ul class="wp-block-list">
<li>In contrast to its bullish cousin, the inverse AMZD ETF has struggled in the past month, losing nearly 19% of market value.</li>
<li>At the moment, AMZD finds itself below both its 50 and 200 DMAs. Ideally, the ETF must get above the $13 level soon to avoid serious technical damage.</li>
</ul>
<figure class="wp-block-image"><img loading="lazy" decoding="async" width="1030" height="627" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21080949/image-263.png" alt="" class="wp-image-922681" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21080949/image-263.png 1030w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21080949/image-263-300x183.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21080949/image-263-1024x624.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21080949/image-263-768x468.png 768w" sizes="(max-width: 1030px) 100vw, 1030px" /></figure>
Featured image by <a href="https://pixabay.com/users/tungart7-38741244/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=8676517">Tung Lam</a> from <a href="https://pixabay.com/illustrations/e-commerce-shopping-parcels-8676517/">Pixabay</a>

Long Ideas

Short Ideas

Technicals

Trading Ideas

ETFs

AMZD

AMZN

AMZU

An Economic Crossroads Puts Direxion's AMZN-Focused Bull And Bear Funds In The Spotlight

<ul>
<li>Complete suite of IHC testing for key biomarkers in all solid tumors, including c-MET, now available in addition to Guardant360 Tissue multiomic profiling test</li>
</ul>
Guardant Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>), a leading precision oncology company, today announced the addition of a full suite of immunohistochemistry (IHC) testing to the company's portfolio of tumor molecular profiling tests. This new set of tests will help oncologists identify tumor subtypes and match cancer patients to the most effective targeted therapies.
IHC testing is a special staining process that detects specific proteins within a tissue sample, known as tumor biomarkers, that can be used to determine the characteristics of a tumor and identify the most appropriate targeted cancer therapy. The new Guardant IHC test suite provides comprehensive testing for key biomarkers in all solid tumors (such as lung, breast, gastric and ovarian cancers). This includes c-MET, the target of Emrelis&#x2122; (telisotuzumab vedotin-tllv), an antibody-drug conjugate recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of c-MET-expressing non-squamous non-small cell lung cancer (NSCLC).
The comprehensive IHC menu covers the following biomarkers: HER2, MMR, PD-L1, c-MET, ER, PR, Ki-67, CLDN18, and FOLR1.

Guardant Health Adds Full Suite Of Immunohistochemistry Testing To Portfolio Of Tumor Molecular Profiling Tests

Jefferies analyst David Chiaverini initiates coverage on First Foundation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FFWM#NYSE">FFWM</a>) with a Buy rating and announces Price Target of $7.

FFWM

Jefferies Initiates Coverage On First Foundation with Buy Rating, Announces Price Target of $7

BancFirst Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BANF#NASDAQ">BANF</a>) today announced it has entered into an agreement to acquire American Bank of Oklahoma (ABOK), a privately held community bank headquartered in Collinsville, Oklahoma. ABOK has approximately $385 million in total assets, $280 million in loans, and $320 million in deposits. The transaction is expected to close in the third quarter of 2025, subject to regulatory approvals and customary closing conditions.
David Harlow, CEO of BancFirst Corporation, commented: "Collinsville and Skiatook are thriving communities that continue to experience dynamic growth in&nbsp;Northeastern Oklahoma. We are excited to welcome the American Bank of Oklahoma team&nbsp;and their customers to BancFirst. This acquisition aligns with our continued commitment to serving communities here in our home state."
Teresa Brown, President &amp; CEO of American Bank of Oklahoma, added: "Joining forces with BancFirst represents a great opportunity for our customers and employees to join one of the strongest banks in the country. We share common values and a commitment to local service, and we look forward to the partnership."
American Bank of Oklahoma will operate under its present name until it is merged into BancFirst, which is expected to be in the fourth quarter of 2025. Customers will receive additional information in the coming months to ensure a seamless transition.

BANF

Bancfirst Corporation Enters Into An Agreement To Acquire American Bank Of Oklahoma, Transaction Is Expected To Close In the Third Quarter of 2025. Terms Not Disclosed

<h3>Gainers</h3>
<ul>
<li>J-Long Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JL#NASDAQ">JL</a>) stock moved upwards by 9.9% to $5.08 during Wednesday's pre-market session. The market value of their outstanding shares is at $15.9 million. </li>
<li>U Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCAR#NASDAQ">UCAR</a>) shares rose 9.65% to $3.18. The company's market cap stands at $13.4 million. </li>
<li>Birks Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BGI#AMEX">BGI</a>) stock moved upwards by 8.6% to $1.01. The company's market cap stands at $19.3 million. </li>
<li>Big 5 Sporting Goods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGFV#NASDAQ">BGFV</a>) shares rose 7.43% to $1.3. The company's market cap stands at $29.7 million. </li>
<li>XPeng (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) shares increased by 4.62% to $20.6. The company's market cap stands at $19.5 billion. As per the news, the Q1 earnings report came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Neo-Concept International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCI#NASDAQ">NCI</a>) shares fell 19.1% to $0.35 during Wednesday's pre-market session. The company's market cap stands at $7.1 million. </li>
<li>VF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) stock declined by 13.03% to $12.55. The company's market cap stands at $4.8 billion. The company's, Q4 earnings came out today. </li>
<li>Carter's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRI#NYSE">CRI</a>) shares decreased by 9.82% to $33.16. The company's market cap stands at $1.2 billion. </li>
<li>Mullen Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) shares fell 7.37% to $0.18. As per the press release, Q2 earnings came out yesterday. </li>
<li>Purple Innovation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPL#NASDAQ">PRPL</a>) stock decreased by 6.41% to $0.84. The company's market cap stands at $90.9 million. </li>
<li>Amesite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMST#NASDAQ">AMST</a>) stock declined by 6.34% to $3.09. The company's market cap stands at $12.3 million. The company's, Q3 earnings came out 4 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AMST

BGFV

MULN

PRPL

UCAR

XPEV

11 Consumer Discretionary Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) stock rose 45.4% to $0.39 during Wednesday's pre-market session. The company's market cap stands at $57.7 million. </li>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) shares moved upwards by 42.5% to $0.18. As per the news, the Q1 earnings report came out 4 days ago. </li>
<li>Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) stock moved upwards by 33.67% to $20.35. The company's market cap stands at $122.5 million. </li>
<li>Akoya Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKYA#NASDAQ">AKYA</a>) shares moved upwards by 22.64% to $1.3. The company's market cap stands at $64.8 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares moved upwards by 19.23% to $0.01. </li>
<li>Immuron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRN#NASDAQ">IMRN</a>) stock moved upwards by 12.11% to $1.8. The market value of their outstanding shares is at $10.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>INVO Fertility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVF#NASDAQ">IVF</a>) shares declined by 12.7% to $1.9 during Wednesday's pre-market session. The company's market cap stands at $9.3 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) stock declined by 11.75% to $1.45. The company's market cap stands at $121.1 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares decreased by 9.16% to $6.25. The company's market cap stands at $3.6 million. </li>
<li>Inventiva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVA#NASDAQ">IVA</a>) shares decreased by 9.06% to $3.0. The market value of their outstanding shares is at $417.1 million. </li>
<li>HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) shares fell 9.04% to $1.51. The market value of their outstanding shares is at $51.0 million. </li>
<li>Akso Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHG#NASDAQ">AHG</a>) shares declined by 8.13% to $1.52. The company's market cap stands at $606.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKYA

BDSX

BEAT

EDIT

IMRN

KDLY

PLRZ

PTIX

PTPI

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Transom Capital Group, LLC ("Transom"), an operationally focused middle-market private equity firm, and SigmaTron International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMA#NASDAQ">SGMA</a>) (the "Company" or "SigmaTron"), an electronic manufacturing services company, today announced that they have entered into a merger agreement pursuant to which an affiliate of Transom will acquire the Company.
Under the terms of the merger agreement, which has been unanimously approved by the Company's Board of Directors, an affiliate of Transom will commence a tender offer to acquire all outstanding shares of the Company's common stock, par value $0.01 per share (the "Common Stock"), for $3.02 per share in cash, representing a total enterprise value of approximately $83 million. The purchase price represents a premium of approximately 134% over the Company's closing market price on May 20, 2025, and approximately 136% over the Company's 30-day volume-weighted average price.
Transaction Details
The transaction is expected to close during the third quarter of 2025, subject to the successful completion of the tender offer and other customary closing conditions. Following completion of the merger, the Company will be wholly owned by Transom and its shares will no longer be listed on Nasdaq.
The transaction is subject to the Company's stockholders validly tendering shares of Common Stock representing at least a majority of the voting power of the Company and other customary closing conditions.
Following the successful closing of the tender offer, an affiliate of Transom will acquire any shares of the Company that are not tendered in the tender offer through a second-step merger for the same consideration as paid in the tender offer.
The Company's Board of Directors unanimously recommends that the Company's stockholders tender their shares in the tender offer.
Further information regarding the terms and conditions in the definitive transaction agreement will be provided in the tender offer materials on Schedule TO and Schedule 14D-9, which will be filed with the U.S. Securities and Exchange Commission (the "SEC") in connection with the transaction.

SGMA

Transom To Commence Tender Offer To Acquire All Outstanding Shares Of SigmaTron For $3.02/Shr In Cash, Representing Total Enterprise Value Of About $83M

<h3>Gainers</h3>
<ul>
<li>YY Group Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YYGH#NASDAQ">YYGH</a>) shares moved upwards by 11.1% to $1.7 during Wednesday's pre-market session. The company's market cap stands at $65.0 million. </li>
<li>Aqua Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQMS#NASDAQ">AQMS</a>) shares rose 8.59% to $1.01. The market value of their outstanding shares is at $8.9 million. </li>
<li>Hyperscale Data (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#AMEX">GPUS</a>) shares moved upwards by 7.37% to $4.95. The company's market cap stands at $8.4 million. The company's, Q1 earnings came out yesterday. </li>
<li>PS International Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) shares increased by 6.69% to $0.34. The market value of their outstanding shares is at $8.1 million. </li>
<li>Dycom Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DY#NYSE">DY</a>) stock moved upwards by 5.87% to $205.0. The market value of their outstanding shares is at $5.9 billion. The company's, Q1 earnings came out today. </li>
<li>JELD-WEN Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JELD#NYSE">JELD</a>) stock increased by 5.44% to $4.07. The company's market cap stands at $347.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Expion360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) stock decreased by 10.7% to $0.8 during Wednesday's pre-market session. The company's market cap stands at $2.5 million. The company's, Q1 earnings came out 4 days ago. </li>
<li>Click Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLIK#NASDAQ">CLIK</a>) stock fell 9.16% to $0.64. The market value of their outstanding shares is at $20.1 million. </li>
<li>Freightos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) stock declined by 8.99% to $2.33. The company's market cap stands at $116.5 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Orion Group Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORN#NYSE">ORN</a>) shares declined by 7.82% to $7.78. The market value of their outstanding shares is at $303.3 million. </li>
<li>Centuri Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRI#NYSE">CTRI</a>) shares declined by 7.2% to $18.19. The company's market cap stands at $1.6 billion. </li>
<li>Ideal Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPWR#NASDAQ">IPWR</a>) shares decreased by 5.98% to $4.8. The market value of their outstanding shares is at $40.0 million. As per the news, the Q1 earnings report came out 4 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AQMS

CLIK

CRGO

CTRI

GPUS

IPWR

JELD

PSIG

XPON

YYGH

12 Industrials Stocks Moving In Wednesday's Pre-Market Session

<a href="https://www.globenewswire.com/Tracker?data=4lf9VQg8mG2w9RIAHGGTNfFkTWFnBJkq4EVd7t6cqO_q4m44g-2sAreo_YazkyWsON0IqhGOunPZp4_kgA6MA9Y1o1zP6QRYSZUVJJmBYVU=">Genius Group Limited</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNS#NYSE">GNS</a>) ("Genius Group" or the "Company"), a leading AI-powered, Bitcoin-first education group,&nbsp;today announced that its lawyers have filed an amended complaint against Peter Ritz and Michael Moe as the controlling officers and directors of LZGI International, Inc ("LZG") under the Racketeer Influenced and Corrupt Organizations Act (RICO), in the United States District Court, Southern District of Florida, seeking updated damages of over $750 million (which includes treble damages potentially recoverable under federal statute) caused by the defendants to Genius Group.
The amended complaint also includes two additional defendants, Michael Carter and John Clayton, who is also a defendant in the case filed by the United States and Exchange Commission ("SEC"), alleging Securities Fraud in the United States District Court District of Utah, Central Division (Case No: 2:24-cv-918). The SEC case against Clayton alleges he and other parties engaged in a securities fraud scheme to secretly amass and then illegally sell stock of small, publicly traded companies including LZGI. Genius Group alleges in its amended filing that both individuals are a part of the RICO enterprise related to the LZGI transaction with the Company.

Legal

Genius Group Files Amended RICO Complaint Seeking Over $750M In Damages Against LZGI Leaders

<h3>Gainers</h3>
<ul>
<li>D-Wave Quantum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) stock moved upwards by 9.5% to $18.14 during Wednesday's pre-market session. The market value of their outstanding shares is at $5.3 billion. </li>
<li>Greenidge Generation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GREE#NASDAQ">GREE</a>) shares rose 9.52% to $1.38. The company's market cap stands at $15.7 million. The company's, Q1 earnings came out 4 days ago. </li>
<li>Rackspace Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXT#NASDAQ">RXT</a>) shares increased by 9.16% to $1.31. The market value of their outstanding shares is at $310.9 million. </li>
<li>Nukkleus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUKK#NASDAQ">NUKK</a>) stock moved upwards by 7.26% to $20.81. The company's market cap stands at $104.5 million. </li>
<li>Oblong (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBLG#NASDAQ">OBLG</a>) shares increased by 7.14% to $3.88. The market value of their outstanding shares is at $5.1 million. </li>
<li>BTCS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCS#NASDAQ">BTCS</a>) shares rose 6.71% to $2.86. The company's market cap stands at $60.3 million. The company's, Q1 earnings came out 4 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Wolfspeed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) stock declined by 62.9% to $1.16 during Wednesday's pre-market session. The market value of their outstanding shares is at $180.5 million. </li>
<li>LeddarTech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LDTC#NASDAQ">LDTC</a>) stock declined by 34.83% to $0.34. The company's market cap stands at $12.5 million. </li>
<li>Signing Day Sports (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SGN#AMEX">SGN</a>) stock fell 13.97% to $0.52. The company's market cap stands at $1.0 million. As per the news, the Q1 earnings report came out 4 days ago. </li>
<li>Sigmatron Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMA#NASDAQ">SGMA</a>) stock declined by 9.31% to $1.17. The company's market cap stands at $7.1 million. </li>
<li>CI&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CINT#NYSE">CINT</a>) shares decreased by 8.88% to $5.85. The company's market cap stands at $787.9 million. </li>
<li>NOVONIX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVX#NASDAQ">NVX</a>) shares fell 8.76% to $1.25. The market value of their outstanding shares is at $198.7 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BTCS

CINT

GREE

LDTC

NUKK

Nuveen California Dividend Advantage Municipal Fund 2

OBLG

QBTS

WOLF

12 Information Technology Stocks Moving In Wednesday's Pre-Market Session

RILY

B. Riley Financial Enters Bond Exchange Agreement With Institutional Investor, Reducing Total Outstanding Debt By ~$46M

Jefferies analyst David Chiaverini initiates coverage on First Citizens BancShares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>) with a Hold rating and announces Price Target of $2050.

FCNCA

Jefferies Initiates Coverage On First Citizens BancShares with Hold Rating, Announces Price Target of $2050

MTD moves up over 20 points on a flat day for the broad market
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/20210844/Screenshot-2025-05-20-at-5.00.12%E2%80%AFPM-914x1024.png" alt="" class="wp-image-13204" /></figure>
Mettler &#8211; Toledo International Inc. (MTD) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.&nbsp;
Today, at 09:03 AM on May 20th, a significant trading signal occurred for Mettler-Toledo International Inc., (MTD) as it demonstrated a Power Inflow at a price of $1169.08. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in MTD's stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in MTD's stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock's overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for MTD, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like <a href="https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_May2025">https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_May2025</a>, which are responsible for parts of the data within this article.
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved
After Market Close UPDATE:
The price at the time of the Power Inflow was $1169.08. The returns on the High price ($1192.46) and Close price ($1186) after the Power Inflow are respectively 2% and 1.4%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite.
Results are not indicative of future results

Equities

WIIM

Opinion

Signals

Mettler-Toledo International Rises 2% After Key Signal

Pyxis Tankers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXS#NASDAQ">PXS</a>) reported quarterly earnings of $0.07 per share. This is a 76.67 percent decrease over earnings of $0.30 per share from the same period last year. The company reported quarterly sales of $9.61 million which missed the analyst consensus estimate of $11.26 million by 14.70 percent. This is a 18.64 percent decrease over sales of $11.80 million the same period last year.

Earnings

Earnings Misses

Pyxis Tankers Q1 EPS $0.07 Down From $0.30 YoY, Sales $9.61M Miss $11.26M Estimate

Press Releases

Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency

Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights

BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

Shareholder Alert: The Ademi Firm investigates whether Inozyme Pharma, Inc. is obtaining a Fair Price for its Public Shareholders

INZY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inozyme Pharma, Inc. Is Fair to Shareholders

Synergy CHC Corp. (NASDAQ: SNYR) Reports Strong Q1, Signals 2025 Expansion in GLP-1 and Global Markets – More Stocks Inside

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHTR and INZY on Behalf of Shareholders

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Inozyme Pharma, Inc. - INZY

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWTX, NVEE, CHTR, INZY on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TXNM, SVT, INZY, PTIX on Behalf of Shareholders

Comments

Inozyme Pharma

Vendite allo scoperto

Inozyme Pharma (NASDAQ:INZY) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO